Linking DNA adduct formation and human cancer risk in chemical carcinogenesis

Environmental and Molecular Mutagenesis

Volumn 57, Issue 7, 2016, Pages 499-507

  Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemical carcinogen; DNA adduct; molecular cancer epidemiology; molecular dosimetry

Indexed keywords

CARCINOGEN;

CANCER EPIDEMIOLOGY; CANCER RISK; CHEMICAL CARCINOGENESIS; DNA ADDUCT; DNA DAMAGE; DOSIMETRY; EXPERIMENTAL MODEL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DOSIMETRY; NONHUMAN; REVIEW;

EID: 84981225497     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.22030     Document Type: Review

References (82)

1. Agudo A, Peluso M, Munnia A, Lujan-Barroso L, Sanchez MJ, Molina-Montes E, Sanchez-Cantalejo E, Navarro C, Tormo MJ, Chirlaque MD, et al. 2012. Aromatic DNA adducts and risk of gastrointestinal cancers: A case-cohort study within the EPIC-Spain. Cancer Epidemiol Biomarkers Prev 21:685–692.
2. Avery OT, Macleod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79:137–158.
3. Balbo S, Turesky RJ, Villalta PW. 2014. DNA adductomics. Chem Res Toxicol 27:356–366.
4. Balmain A, Yuspa SH. 2014. Milestones in skin carcinogenesis: The biology of multistage carcinogenesis. J Invest Dermatol 134:E2–E7.
5. Beland FA, Poirier MC. 1993. Significance of DNA adduct studies in animal models for cancer molecular dosimetry and risk assessment. Environ Health Perspect 99:5–10.
6. Boutwell RK. 1989. Model systems for defining initiation, promotion, and progression of skin neoplasms. Prog Clin Biol Res 298:3–15.
7. Boysen G, Hecht SS. 2003. Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutat Res 543:17–30.
8. Boysen G, Kenney PM, Upadhyaya P, Wang M, Hecht SS. 2003. Effects of benzyl isothiocyanate and 2-phenethyl isothiocyanate on benzo[a]pyrene and 4-(methylnitrosamino)−1-(3-pyridyl)−1-butanone metabolism in F-344 rats. Carcinogenesis 24:517–525.
9. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP, et al. 2012. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109:8241–8246.
10. Chen L, Wang M, Villalta PW, Luo X, Feuer R, Jensen J, Hatsukami DK, Hecht SS. 2007. Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem Res Toxicol 20:108–113.
11. Chen SY, Wang LY, Lunn RM, Tsai WY, Lee PH, Lee CS, Ahsan H, Zhang YJ, Chen CJ, Santella RM. 2002. Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 99:14–21.
12. Cleaver JE. 2005. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5:564–573.
13. DeMarini DM. 2013. Genotoxicity biomarkers associated with exposure to traffic and near-road atmospheres: A review. Mutagenesis 28:485–505.
14. Dingley KH, Roberts ML, Velsko CA, Turteltaub KW. 1998. Attomole detection of 3H in biological samples using accelerator mass spectrometry: Application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry. Chem Res Toxicol 11:1217–1222.
15. Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, et al. 2001. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci USA 98:14601–14606.
16. Farmer PB, Singh R. 2008. Use of DNA adducts to identify human health risk from exposure to hazardous environmental pollutants: The increasing role of mass spectrometry in assessing biologically effective doses of genotoxic carcinogens. Mutat Res 659:68–76.
17. Farmer PB, Sepai O, Lawrence R, Autrup H, Sabro Nielsen P, Vestergard AB, Waters R, Leuratti C, Jones NJ, Stone J, Baan RA, Van Delft JH, Steenwinkel MJ, Kyrtopoulos SA, Souliotis VL, Theodorakopoulos N, Bacalis NC, Natarajan AT, Tates AD, Haugen A, et al. 1996. Biomonitoring human exposure to environmental carcinogenic chemicals. Mutagenesis 11:363–381.
18. Farmer PB, Singh R, Kaur B, Sram RJ, Binkova B, Kalina I, Popov TA, Garte S, Taioli E, Gabelova A, Cebulska-Wasilewska A. 2003. Molecular epidemiology studies of carcinogenic environmental pollutants. Effects of polycyclic aromatic hydrocarbons (PAHs) in environmental pollution on exogenous and oxidative DNA damage. Mutat Res 544:397–402.
19. Fung C, Fossa SD, Williams A, Travis LB. 2015. Long-term morbidity of testicular cancer treatment. Urol Clin North Am 42:393–408.
20. Gallo V, Khan A, Gonzales C, Phillips DH, Schoket B, Gyorffy E, Anna L, Kovacs K, Moller P, Loft S, et al. 2008. Validation of biomarkers for the study of environmental carcinogens: A review. Biomarkers 13:505–534.
21. Gammon MD, Sagiv SK, Eng SM, Shantakumar S, Gaudet MM, Teitelbaum SL, Britton JA, Terry MB, Wang LW, Wang Q, et al. 2004. Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: A pooled analysis. Arch Environ Health 59:640–649.
22. Garcia-Suastegui WA, Huerta-Chagoya A, Carrasco-Colin KL, Pratt MM, John K, Petrosyan P, Rubio J, Poirier MC, Gonsebatt ME. 2011. Seasonal variations in the levels of PAH-DNA adducts in young adults living in Mexico City. Mutagenesis 26:385–391.
23. Groopman JD, Kensler TW. 1999. The light at the end of the tunnel for chemical-specific biomarkers: Daylight or headlight? Carcinogenesis 20:1–11.
24. Groopman JD, Sabbioni G, Wild CP. 1991. Molecular dosimetry of human aflatoxin exposures. In: Groopman JD, editor. Molecular Dosimetry and Human Cancer. Boca Raton: CRC Press. pp 303–324.
25. Gunter MJ, Divi RL, Kulldorff M, Vermeulen R, Haverkos KJ, Kuo MM, Strickland P, Poirier MC, Rothman N, Sinha R. 2007. Leukocyte polycyclic aromatic hydrocarbon-DNA adduct formation and colorectal adenoma. Carcinogenesis 28:1426–1429.
26. Guo J, Yun BH, Upadhyaya P, Yao L, Krishnamachari S, Rosenquist TA, Grollman AP, Turesky RJ. 2016. Multiclass carcinogenic DNA adduct quantification in formalin-fixed paraffin-embedded tissues by ultraperformance liquid chromatography-tandem mass spectrometry. Anal Chem 88:4780–4787.
27. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. 2000. Dna adducts, mutations, and cancer 2000. Regul Toxicol Pharmacol 32:264–275.
28. Jalal S, Earley JN, Turchi JJ. 2011. DNA repair: From genome maintenance to biomarker and therapeutic target. Clin Cancer Res 17:6973–6984.
29. Jarabek AM, Pottenger LH, Andrews LS, Casciano D, Embry MR, Kim JH, Preston RJ, Reddy MV, Schoeny R, Shuker D, et al. 2009. Creating context for the use of DNA adduct data in cancer risk assessment: I. Data organization. Crit Rev Toxicol 39:659–678.
30. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, Tomic K, Slade N, Brdar B, Turesky RJ, et al. 2012. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81:559–567.
31. Kang DH, Rothman N, Poirier MC, Greenberg A, Hsu CH, Schwartz BS, Baser ME, Groopman JD, Weston A, Strickland PT. 1995. Interindividual differences in the concentration of 1-hydroxypyrene-glucuronide in urine and polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells after charbroiled beef consumption. Carcinogenesis 16:1079–1085.
32. King HW, Osborne MR, Beland FA, Harvey RG. 1976. Brookes P. (+/-)−7alpha,8beta-dihydroxy-9beta,10beta-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyren e is an intermediate in the metabolism and binding to DNA of benzo(a)pyrene. Proc Natl Acad Sci USA 73:2679–2681.
33. Kriek E, Rojas M, Alexandrov K, Bartsch H. 1998. Polycyclic aromatic hydrocarbon-DNA adducts in humans: Relevance as biomarkers for exposure and cancer risk. Mutat Res 400:215–231.
34. Liou SH, Jacobson-Kram D, Poirier MC, Nguyen D, Strickland PT, Tockman MS. 1989. Biological monitoring of fire fighters: Sister chromatid exchange and polycyclic aromatic hydrocarbon-DNA adducts in peripheral blood cells. Cancer Res 49:4929–4935.
35. Loeb KR, Loeb LA. 2000. Significance of multiple mutations in cancer. Carcinogenesis 21:379–385.
36. Magee PN, Farber E. 1962. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem J 83:114–124.
37. Maher VM, McCormick JJ. 1975. Cytotoxic and mutagenic effects of carcinogenic aromatic amides and polycyclic hydrocarbons and ultraviolet irradiation in normally repairing and repair-deficient (xeroderma pigmentosum) diploid human skin fibroblasts. Basic Life Sci 5B:785–787.
38. Maher VM, Mccormick JJ. 1984. Role of DNA lesions and repair in the transformation of human cells. Pharmacol Ther 25:395–408.
39. Maher VM, McCormick JJ. 1986. Role of DNA lesions and DNA repair in mutagenesis by carcinogens in diploid human fibroblasts. Prog Clin Biol Res 209A:245–253.
40. Maher VM, Mccormick JJ, Grover PL, Sims P. 1977. Effect of DNA repair on the cytotoxicity and mutagenicity of polycyclic hydrocarbon derivatives in normal and xeroderma pigmentosum human fibroblasts. Mutat Res 43:117–138.
41. Manchester DK, Wilson VL, Hsu IC, Choi JS, Parker NB, Mann DL, Weston A, Harris CC. 1990. Synchronous fluorescence spectroscopic, immunoaffinity chromatographic and 32P-postlabeling analysis of human placental DNA known to contain benzo[a]pyrene diol epoxide adducts. Carcinogenesis 11:553–559.
42. Miller JA. 1994. Research in chemical carcinogenesis with Elizabeth Miller–a trail of discovery with our associates. Drug Metab Rev 26:1–36.
43. Miller JA. 1998. The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: A collaboration with Elizabeth Cavert Miller and our associates. Drug Metab Rev 30:645–674.
44. Molina E, Perez-Morales R, Rubio J, Petrosyan P, Cadena LH, Arlt VM, Phillips DH, Gonsebatt ME. 2013. The GSTM1null (deletion) and MGMT84 rs12917 (Phe/Phe) haplotype are associated with bulky DNA adduct levels in human leukocytes. Mutat Res 758:62–68.
45. Moller L, Grzybowska E, Zeisig M, Cimander B, Hemminki K, Chorazy M. 1996. Seasonal variation of DNA adduct pattern in human lymphocytes analyzed by 32P-HPLC. Carcinogenesis 17:61–66.
46. Moss SF, Blaser MJ. 2005. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2:90–97. quiz 91 p following 113.
47. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G, Vineis P. 1998. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: A case-control study. Cancer Epidemiol Biomarkers Prev 7:341–346.
48. Peluso M, Ceppi M, Munnia A, Puntoni R, Parodi S. 2001. Analysis of 13 (32)P-DNA postlabeling studies on occupational cohorts exposed to air pollution. Am J Epidemiol 153:546–558.
49. Peluso M, Munnia A, Hoek G, Krzyzanowski M, Veglia F, Airoldi L, Autrup H, Dunning A, Garte S, Hainaut P, et al. 2005. DNA adducts and lung cancer risk: A prospective study. Cancer Res 65:8042–8048.
50. Perera FP, Poirier MC, Yuspa SH, Nakayama J, Jaretzki A, Curnen MM, Knowles DM, Weinstein IB. 1982. A pilot project in molecular cancer epidemiology: Determination of benzo[a]pyrene–DNA adducts in animal and human tissues by immunoassays. Carcinogenesis 3:1405–1410.
51. Phillips DH. 2002. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 23:1979–2004.
52. Poirier MC, Yuspa SH, Weinstein IB, Blobstein S. 1977. Detection of carcinogen-DNA adducts by radiommunoassay. Nature 270:186–188.
53. Poirier MC, Reed E, Ozols RF, Fasy T, Yuspa SH. 1987. DNA adducts of cisplatin in nucleated peripheral blood cells and tissues of cancer patients. Prog Exp Tumor Res 31:104–113.
54. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. 1992. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149–153.
55. Poirier MC, Weston A, Schoket B, Shamkhani H, Pan CF, Mcdiarmid MA, Scott BG, Deeter DP, Heller JM, Jacobson-Kram D, Rothman N. 1998. Biomonitoring of United States Army soldiers serving in Kuwait in 1991. Cancer Epidemiol Biomarkers Prev 7:545–551.
56. Poirier MC, Santella RM, Weston A. 2000. Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21:353–359.
57. Potter M. 1963. Percivall Pott's contribution to cancer research. Natl Cancer Inst Monogr 10:1–13.
58. Pratt MM, John K, Maclean AB, Afework S, Phillips DH, Poirier MC. 2011. Polycyclic aromatic hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues. Int J Environ Res Public Health 8:2675–2691.
59. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3–10.
60. Randerath K, Randerath E. 1994. 32P-postlabeling methods for DNA adduct detection: Overview and critical evaluation. Drug Metab Rev 26:67–85.
61. Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. 1986. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77:545–550.
62. Rojas M, Alexandrov K, Auburtin G, Wastiaux-Denamur A, Mayer L, Mahieu B, Sebastien P, Bartsch H. 1995. Anti-benzo[a]pyrene diolepoxide–DNA adduct levels in peripheral mononuclear cells from coke oven workers and the enhancing effect of smoking. Carcinogenesis 16:1373–1376.
63. Rothman N, Poirier MC, Baser ME, Hansen JA, Gentile C, Bowman ED, Strickland PT. 1990. Formation of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during consumption of charcoal-broiled beef. Carcinogenesis 11:1241–1243.
64. Santella RM. 1999. Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol Biomarkers Prev 8:733–739.
65. Santella RM, Grinberg-Funes RA, Young TL, Dickey C, Singh VN, Wang LW, Perera FP. 1992. Cigarette smoking related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells. Carcinogenesis 13:2041–2045.
66. Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S. 2012. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen 53:636–641.
67. Schmeiser HH, Nortier JL, Singh R, Gamboa Da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, et al. 2014. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 135:502–507.
68. Schoket B, Papp G, Levay K, Mrackova G, Kadlubar FF, Vincze I. 2001. Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutat Res 482:57–69.
69. Sims P, Grover PL, Swaisland A, Pal K, Hewer A. 1974. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature 252:326–328.
70. Stewart BW, Bray F, Forman D, Ohgaki H, Straif K, Ullrich A, Wild CP. 2016. Cancer prevention as part of precision medicine: 'plenty to be done'. Carcinogenesis 37:2–9.
71. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, Grantham S, Tsai WY, Perera FP. 1995. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prev 4:341–346.
72. Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, Tsai WY, Ma J, Cole KJ, She MN, Perera FP. 2001. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res 61:6708–6712.
73. Tang D, Kryvenko ON, Wang Y, Jankowski M, Trudeau S, Rundle A, Rybicki BA. 2013. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis 34:113–120.
74. Veglia F, Loft S, Matullo G, Peluso M, Munnia A, Perera F, Phillips DH, Tang D, Autrup H, Raaschou-Nielsen O, Tjonneland A, Vineis P, Genair EI. 2008. DNA adducts and cancer risk in prospective studies: A pooled analysis and a meta-analysis. Carcinogenesis 29:932–936.
75. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789–799.
76. Wang LY, Chen CJ, Zhang YJ, Tsai WY, Lee PH, Feitelson MA, Lee CS, Santella RM. 1998. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol 147:315–323.
77. Watson JD, Crick FH. 1953. The structure of DNA. Cold Spring Harb Symp Quant Biol 18:123–131.
78. Weston A, Manchester DK, Poirier MC, Choi JS, Trivers GE, Mann DL, Harris CC. 1989. Derivative fluorescence spectral analysis of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Chem Res Toxicol 2:104–108.
79. Wu S, Powers S, Zhu W, Hannun YA. 2016. Substantial contribution of extrinsic risk factors to cancer development. Nature 529:43–47.
80. Yun BH, Rosenquist TA, Nikolic J, Dragicevic D, Tomic K, Jelakovic B, Dickman KG, Grollman AP, Turesky RJ. 2013. Human formalin-fixed paraffin-embedded tissues: An untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry. Anal Chem 85:4251–4258.
81. Yun BH, Yao L, Jelakovic B, Nikolic J, Dickman KG, Grollman AP, Rosenquist TA, Turesky RJ. 2014. Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: Aristolochic acid as a prototype carcinogen. Carcinogenesis 35:2055–2061.
82. Zhu J, Chang P, Bondy ML, Sahin AA, Singletary SE, Takahashi S, Shirai T, Li D. 2003. Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 12:830–837.